{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:47:42Z","timestamp":1793346462257,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.atherosclerosis.2026.120686","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:08:27Z","timestamp":1772582907000},"page":"120686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["LDL subspecies and lipidome change by evolocumab add-on therapy to empagliflozin in patients with type 2 diabetes: A prespecified secondary analysis of a randomized clinical trial"],"prefix":"10.1016","volume":"415","author":[{"given":"Isabella","family":"Bonilha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Yukio","family":"Yoshinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano Britto","family":"Chaves-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9rica Ivana L\u00e1zaro","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosangela Silva","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikaro","family":"Breder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Breder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Nadruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatol","family":"Kontush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7127-2052","authenticated-orcid":false,"given":"Andrei C.","family":"Sposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9733","key":"10.1016\/j.atherosclerosis.2026.120686_bib1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120686_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management","volume":"21","author":"Ma","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2026.120686_bib3","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2026.120686_bib4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2026.120686_bib5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jchf.2021.03.003","article-title":"Patient phenotypes and SGLT-2 inhibition in type 2 diabetes: insights from the EMPA-REG OUTCOME trial","volume":"9","author":"Sharma","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2026.120686_bib6","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1111\/dom.13488","article-title":"Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component?","volume":"20","author":"Prattichizzo","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120686_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005066","article-title":"Ketone body infusion with 3-Hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: a positron emission tomography study","volume":"6","author":"Gormsen","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosis.2026.120686_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117236","article-title":"SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type","volume":"394","author":"Bechmann","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120686_bib9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s44161-022-00085-x","article-title":"Chasing LDL cholesterol to the bottom \u2014 PCSK9 in perspective","volume":"1","author":"Libby","year":"2022","journal-title":"Nat Cardiovasc Res"},{"issue":"9965","key":"10.1016\/j.atherosclerosis.2026.120686_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2026.120686_bib11","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120686_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.atherosclerosis.2018.01.004","article-title":"PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions","volume":"269","author":"Hilvo","year":"2018","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2026.120686_bib13","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1210\/jc.2003-030636","article-title":"Low-density lipoprotein size and cardiovascular disease: a reappraisal","volume":"88","author":"Sacks","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"27","key":"10.1016\/j.atherosclerosis.2026.120686_bib14","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1093\/eurheartj\/ehy319","article-title":"Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths","volume":"39","author":"Ruuth","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120686_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320959248","article-title":"Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial","volume":"11","author":"Breder","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120686_bib16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12933-022-01584-8","article-title":"Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial","volume":"21","author":"Sposito","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2026.120686_bib17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0022-2275(20)35376-1","article-title":"A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum","volume":"22","author":"Chapman","year":"1981","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120686_bib18","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1194\/jlr.D800028-JLR200","article-title":"Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry","volume":"50","author":"Wiesner","year":"2009","journal-title":"J Lipid Res"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.120686_bib19","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1194\/jlr.D700041-JLR200","article-title":"Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics","volume":"49","author":"Matyash","year":"2008","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2026.120686_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102277","article-title":"Comprehensive characterization of migration profiles of murine cerebral cortical neurons during development using FlashTag labeling","volume":"24","author":"Yoshinaga","year":"2021","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120686_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48059-7","article-title":"Alterations in lipid metabolism of spinal cord linked to amyotrophic lateral sclerosis","volume":"9","author":"Chaves-Filho","year":"2019","journal-title":"Sci Rep"},{"issue":"30","key":"10.1016\/j.atherosclerosis.2026.120686_bib22","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1093\/eurheartj\/ehz350","article-title":"Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans","volume":"40","author":"Thijssen","year":"2019","journal-title":"Eur Heart J"},{"issue":"W1","key":"10.1016\/j.atherosclerosis.2026.120686_bib23","doi-asserted-by":"crossref","first-page":"W486","DOI":"10.1093\/nar\/gky310","article-title":"MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis","volume":"46","author":"Chong","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120686_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61897-4","article-title":"Effects of phytosterol supplementation on lipoprotein subfractions and LDL particle quality","volume":"14","author":"Machado","year":"2024","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.120686_bib25","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1161\/01.ATV.16.6.794","article-title":"Differences in receptor binding of LDL subfractions","volume":"16","author":"Campos","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2026.120686_bib26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1194\/jlr.M073882","article-title":"Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin","volume":"58","author":"Thongtang","year":"2017","journal-title":"J Lipid Res"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2026.120686_bib27","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of increased LDL (Low-Density lipoprotein) and decreased triglycerides with SGLT2 (Sodium-Glucose cotransporter 2) inhibition","volume":"38","author":"Basu","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120686_bib28","article-title":"SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type","author":"Bechmann","year":"2023","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120686_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-77104-3","article-title":"Gliflozins, sucrose and flavonoids are allosteric activators of lecithin-cholesterol acyltransferase","volume":"14","author":"Niemel\u00e4","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120686_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/oxfordjournals.aje.a115479","article-title":"Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population","volume":"131","author":"Miettinen","year":"1990","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2026.120686_bib31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.atherosclerosis.2013.11.043","article-title":"Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease","volume":"232","author":"Gylling","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120686_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ijcard.2021.01.063","article-title":"Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: association with a slight increase in high-density lipoprotein cholesterol","volume":"331","author":"Jojima","year":"2021","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120686_bib33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-016-0428-z","article-title":"Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases","volume":"15","author":"Girona","year":"2016","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2026.120686_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041816","article-title":"Convergence: lactosylceramide-centric signaling pathways induce inflammation, oxidative stress, and other phenotypic outcomes","volume":"22","author":"Chatterjee","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2026.120686_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111051","article-title":"Effect of diet and genotype on the lipidome of mice with altered lipoprotein metabolism","volume":"27","author":"Busnelli","year":"2024","journal-title":"iScience"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2026.120686_bib36","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1161\/01.ATV.15.10.1607","article-title":"Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis","volume":"15","author":"Mukhin","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120686_bib37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/glycob\/6.3.303","article-title":"Oxidized low density lipoprotein stimulates aortic smooth muscle cell proliferation","volume":"6","author":"Chatterjee","year":"1996","journal-title":"Glycobiology"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2026.120686_bib38","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.113.007559","article-title":"Inhibition of glycosphingolipid synthesis ameliorates atherosclerosis and arterial stiffness in apolipoprotein E-\/- mice and rabbits fed a high-fat and -cholesterol diet","volume":"129","author":"Chatterjee","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2026.120686_bib39","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1021\/cr200084z","article-title":"Free radical lipid peroxidation: mechanisms and analysis","volume":"111","author":"Yin","year":"2011","journal-title":"Chem Rev"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2026.120686_bib40","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1161\/CIRCULATIONAHA.125.073855","article-title":"Oxidized phospholipids, lipoprotein(a), and cardiovascular outcomes after acute coronary syndrome","volume":"152","author":"Tsimikas","year":"2025","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2026.120686_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/jn\/131.2.366S","article-title":"Vitamin E and atherosclerosis: beyond prevention of LDL oxidation","volume":"131","author":"Meydani","year":"2001","journal-title":"J Nutr"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026000523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026000523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:37:58Z","timestamp":1779251878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026000523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":41,"alternative-id":["S0021915026000523"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120686","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LDL subspecies and lipidome change by evolocumab add-on therapy to empagliflozin in patients with type 2 diabetes: A prespecified secondary analysis of a randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120686","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120686"}}